{"Clinical Trial ID": "NCT01004744", "Intervention": ["INTERVENTION 1:", "Oral presurgical anastrozole", "1mg per day for two weeks in the interval between diagnostic breast biopsy and definitive breast surgery.", "Anastrozole: 1 mg PO per day for two weeks prior to scheduled surgery"], "Eligibility": ["Incorporation criteria:", "Invasive breast cancer or in situ channel carcinoma (CDIS), which undergoes a heart needle biopsy followed by surgical excision at least 2 weeks after registration", "A postmenopausal status defined as stopping periods for > 1 year or FSH > 20 mIU/mL (in the previous month)", "21 years of age", "No prior chemotherapy, radiotherapy or surgery within 6 months of entry into the study", "Signed informed consent", "- Exclusion criteria:", "Treatment with other experimental medicinal products within 6 months of entry into the study", "Other serious intercurrent diseases"], "Results": ["Performance measures:", "Number of subjects who completed oral anastrozole 1mg per day for two weeks in the interval between diagnostic breast biopsy and definitive breast surgery", "The number of subjects who completed oral anastrozole during the duration of the study is analyzed. Subjects receive oral anastrozole 1mg per day for two weeks in the interval between biopsy and surgery.", "Time limit: two weeks", "Results 1:", "Title of the arm/group: Pre-surgical oral anastrozole", "Description of the arm/group: 1mg per day for two weeks in the interval between diagnostic breast biopsy and definitive breast surgery.", "Anastrozole: 1 mg PO per day for two weeks prior to scheduled surgery", "Total number of participants analysed: 10", "Type of measurement: Number", "Unit of measurement: participants 10"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/10 (0.00 per cent)"]}